These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29380350)

  • 1. Retrospective study of rapamycin or rapalog 0·1% cream for facial angiofibromas in tuberous sclerosis complex: evaluation of treatment effectiveness and cost.
    Norrenberg S; Masconi M; Karamanou M; Meylan P; Golaz R; Christen-Zaech S
    Br J Dermatol; 2018 Jul; 179(1):208-209. PubMed ID: 29380350
    [No Abstract]   [Full Text] [Related]  

  • 2. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK; O'Brian AL; Teng JM
    Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical sirolimus for the treatment of angiofibromas in tuberous sclerosis.
    Cinar SL; Kartal D; Bayram AK; Canpolat M; Borlu M; Ferahbas A; Per H
    Indian J Dermatol Venereol Leprol; 2017; 83(1):27-32. PubMed ID: 27643542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity.
    Wataya-Kaneda M; Tanaka M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2011 Oct; 165(4):912-6. PubMed ID: 21692771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis.
    Hofbauer GF; Marcollo-Pini A; Corsenca A; Kistler AD; French LE; Wüthrich RP; Serra AL
    Br J Dermatol; 2008 Aug; 159(2):473-5. PubMed ID: 18547304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
    Mutizwa MM; Berk DR; Anadkat MJ
    Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
    [No Abstract]   [Full Text] [Related]  

  • 14. Validation of the Index for Facial Angiofibromas: Data analysis from a randomized controlled trial of sirolimus gel treatment in patients with tuberous sclerosis complex.
    Hamada I; Yukutake Y; Morita Y; Ishikawa N; Shimizu K; Wataya-Kaneda M
    J Dermatol; 2024 Jun; 51(6):752-758. PubMed ID: 38619178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
    Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
    Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
    [No Abstract]   [Full Text] [Related]  

  • 16. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
    Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
    Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas.
    Bouguéon G; Lagarce F; Martin L; Pailhoriès H; Bastiat G; Vrignaud S
    Int J Pharm; 2016 Jul; 509(1-2):279-284. PubMed ID: 27260135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
    Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
    Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
    Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
    Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.